Paid Clinical Trials Rapid City

Discover 80 paid clinical trials in Rapid City, South Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 80

Study with Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure with Severely Reduced Ejection FractionStudy with Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure with Severely Reduced Ejection Fraction

Recruiting

PHASE3

Sponsor:

Cytokinetics

Location:

Rapid City SD, Munster IN, El Paso TX, Richmond INshow 9 more

Code:

NCT06736574

Conditions

Heart Failure

Heart Failure with Reduced Ejection Fraction

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Omecamtiv Mecarbil (OM)

Placebo

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After SurgeryUsing Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Rapid City SD, Billings MT, Englewood CO, Sioux Falls SDshow 109 more

Code:

NCT05111574

Conditions

Anal Melanoma

Bladder Melanoma

Cervical Melanoma

Esophageal Melanoma

Gallbladder Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Scan

Cabozantinib S-malate

Computed Tomography

Echocardiography

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesA Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

Recruiting

PHASE2

Sponsor:

Novo Nordisk A/S

Location:

Rapid City SD, Fargo ND, Chesterfield MO, Chicago ILshow 20 more

Code:

NCT06542874

Conditions

Type 2 Diabetes (T2D)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

NNC0487-0111 subcutanous

Placebo (NNC0487-0111 subcutanous)

NNC0487-0111 oral

Placebo (NNC0487-0111 oral)

Together Overcoming Diabetes - Great PlainsTogether Overcoming Diabetes - Great Plains

Recruiting

Sponsor:

Johns Hopkins Bloomberg School of Public Health

Location:

Rapid City SD

Code:

NCT06770673

Conditions

Diabetes

Eligibility Criteria

Sex: All

Age: 10+

Healthy Volunteers: Not accepted

Interventions

TOD Great Plains

Waitlist Standard of Care

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialChemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Recruiting

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Rapid City SD, Bismarck ND, Billings MT, Sioux Falls SDshow 213 more

Code:

NCT06096844

Conditions

Advanced Lung Non-Small Cell Carcinoma

Stage IIIB Lung Cancer AJCC v8

Stage IIIC Lung Cancer AJCC v8

Stage IV Lung Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 70+

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Computed Tomography

Magnetic Resonance Imaging

Nab-paclitaxel

Paclitaxel

Colon Adjuvant Chemotherapy Based on Evaluation of Residual DiseaseColon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting

PHASE2

PHASE3

Sponsor:

NRG Oncology

Location:

Rapid City SD, Pierre SD, Bismarck ND, Aberdeen SDshow 670 more

Code:

NCT05174169

Conditions

Stage III Colon Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Signatera test

mFOLFOX6 3-6 month

CAPOX 3 month

mFOLFIRINOX

mFOLFOX6 6 month

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsEfficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Rapid City SD, Fargo ND, Salt Lake City UT, Rochester MNshow 68 more

Code:

NCT05166889

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Eligibility Criteria

Sex: All

Age: 40 - 70+

Healthy Volunteers: Not accepted

Interventions

Tozorakimab

Placebo

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral VasculatureDrug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

Recruiting

Sponsor:

Boston Scientific Corporation

Location:

Rapid City SD, Coon Rapids MN, Tulsa OK, Calgaryshow 42 more

Code:

NCT04674969

Conditions

Peripheral Vascular Diseases

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLCTo Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting

PHASE3

Sponsor:

Shanghai Henlius Biotech

Location:

Rapid City SD, Greeley CO, Billings MT, Denver COshow 85 more

Code:

NCT05468489

Conditions

Extensive Stage Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Serplulimab + chemotherapy (carboplatin-etoposide)

Atezolizumab + chemotherapy (carboplatin-etoposide)

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment TrialStudy of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Rapid City SD, Bismarck ND, Billings MT, Sioux Falls SDshow 162 more

Code:

NCT05554380

Conditions

Locally Advanced Malignant Solid Neoplasm

Metastatic Malignant Solid Neoplasm

Unresectable Malignant Solid Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy

Biospecimen Collection

Computed Tomography

Ipatasertib

Magnetic Resonance Imaging